New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
08:18 EDTCLSNCelsion's Thermodox for breast cancer shows positive Phase 2 results
Celsion announced positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer. 60% of patients experienced a stabilization of their highly refractory disease with a local response rate of 50% observed in the 10 evaluable patients, notably 3 complete responses, 2 partial responses and 1 patient with stable disease. These data are consistent with the previously reported positive Phase 1 data in RCWBC.
News For CLSN From The Last 14 Days
Check below for free stories on CLSN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
17:17 EDTCLSNCelsion files to sell 3.38M shares of common stock for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use